Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T17:08:15.383Z.
Calculation as of: 2026-10-06T17:08:15.383Z.
Quote observation: 2026-10-06T17:04:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 352cae2fe5eed9f02885becd1bbca6bb54c51239af0254a5780fc03f1b1dafbc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$104.68M
PS Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$104.45M
PS Ratio
N/A
TTM Avg
514.47
3Y Avg
387.29
5Y Avg
316.66
Market Cap
$96.95M
PS Ratio
41.38
TTM Avg
84.35
3Y Avg
50.99
5Y Avg
44.29
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| OnKure Therapeutics, Inc. (OKUR) | $101.24M | N/A | N/A | N/A | N/A |
| The Joint Corp. (JYNT)vs › | $102.66M | 1.75 | 34.24 | 14.02 | 10.44 |
| PolyPid Ltd. (PYPD)vs › | $98.85M | N/A | N/A | N/A | N/A |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.45M | N/A | 514.47 | 387.29 | 316.66 |
| Conexeu Sciences Inc. (CNXU)vs › | $96.60M | N/A | N/A | N/A | N/A |
| Korro Bio, Inc. (KRRO)vs › | $97.50M | 40.93 | 37.06 | 38.79 | 28.73 |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | 0.45 | 0.67 | 1.87 | 5.03 |
| Milestone Pharmaceuticals Inc. (MIST)vs › | $96.95M | 41.38 | 84.35 | 50.99 | 44.29 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.59M | 3.41 | 1.84 | 1.24 | 1.12 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-12 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-04 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
